- First Dosings completed in Australia
- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences
- Announces 5:1 Share Consolidation Ratio
Field Trip Announces First Dosings in Phase I Clinical Study of FT-104
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here